Cargando…

The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial

OBJECTIVES: To evaluate the immunogenicity of an extended interval regimen of BNT162b2 among healthy school-age children. METHODS: A randomized-control trial conducted among healthy Thai children aged 5-11 years. Participants received two doses of BNT162b2 with an 8-week (extended dosing) vs 3-week...

Descripción completa

Detalles Bibliográficos
Autores principales: Chantasrisawad, Napaporn, Techasaensiri, Chonnamet, Kosalaraksa, Pope, Phongsamart, Wanatpreeya, Tangsathapornpong, Auchara, Jaru-Ampornpan, Peera, Sophonphan, Jiratchaya, Suntarattiwong, Piyarat, Puthanakit, Thanyawee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011807/
https://www.ncbi.nlm.nih.gov/pubmed/36841501
http://dx.doi.org/10.1016/j.ijid.2023.02.017
_version_ 1784906480485400576
author Chantasrisawad, Napaporn
Techasaensiri, Chonnamet
Kosalaraksa, Pope
Phongsamart, Wanatpreeya
Tangsathapornpong, Auchara
Jaru-Ampornpan, Peera
Sophonphan, Jiratchaya
Suntarattiwong, Piyarat
Puthanakit, Thanyawee
author_facet Chantasrisawad, Napaporn
Techasaensiri, Chonnamet
Kosalaraksa, Pope
Phongsamart, Wanatpreeya
Tangsathapornpong, Auchara
Jaru-Ampornpan, Peera
Sophonphan, Jiratchaya
Suntarattiwong, Piyarat
Puthanakit, Thanyawee
author_sort Chantasrisawad, Napaporn
collection PubMed
description OBJECTIVES: To evaluate the immunogenicity of an extended interval regimen of BNT162b2 among healthy school-age children. METHODS: A randomized-control trial conducted among healthy Thai children aged 5-11 years. Participants received two doses of BNT162b2 with an 8-week (extended dosing) vs 3-week interval. Immunogenicity was determined by neutralization test (NT) against the Omicron variant, surrogate virus NT (sVNT; BA.1, % inhibition), and pseudovirus NT (BA.2, the half-maximal inhibition dilution or ID(50)). The third dose was offered to participants who had sVNT <68% inhibition. The immunogenicity outcome was evaluated at 14 days after the second and third doses. RESULTS: During February to April 2022, 382 children with a median age (interquartile range) of 8.4 years (6.6-10.0) were enrolled. At 14 days, after two doses of BNT162b2, the geometric means of sVNT in 8-week vs 3-week interval groups were 49.6 (95% confidence interval [CI] 44.8-54.9) vs 16.5 (95% CI 13.0-20.9), with a geometric means ratio of 3.0 (95% CI 2.4-3.8). Among 102 participants who received the third dose at a median of 15 weeks from the second dose, the geometric means of sVNT increased to 73.3 (95% CI 69.0-77.8) and pseudovirus NT increased to 326 (95% CI 256-415). CONCLUSION: The extended 8-week interval regimen of BNT162b2 induced higher neutralizing antibodies than a standard 3-week interval regimen. The third dose induced high neutralizing antibodies against the Omicron variant.
format Online
Article
Text
id pubmed-10011807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-100118072023-03-14 The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial Chantasrisawad, Napaporn Techasaensiri, Chonnamet Kosalaraksa, Pope Phongsamart, Wanatpreeya Tangsathapornpong, Auchara Jaru-Ampornpan, Peera Sophonphan, Jiratchaya Suntarattiwong, Piyarat Puthanakit, Thanyawee Int J Infect Dis Article OBJECTIVES: To evaluate the immunogenicity of an extended interval regimen of BNT162b2 among healthy school-age children. METHODS: A randomized-control trial conducted among healthy Thai children aged 5-11 years. Participants received two doses of BNT162b2 with an 8-week (extended dosing) vs 3-week interval. Immunogenicity was determined by neutralization test (NT) against the Omicron variant, surrogate virus NT (sVNT; BA.1, % inhibition), and pseudovirus NT (BA.2, the half-maximal inhibition dilution or ID(50)). The third dose was offered to participants who had sVNT <68% inhibition. The immunogenicity outcome was evaluated at 14 days after the second and third doses. RESULTS: During February to April 2022, 382 children with a median age (interquartile range) of 8.4 years (6.6-10.0) were enrolled. At 14 days, after two doses of BNT162b2, the geometric means of sVNT in 8-week vs 3-week interval groups were 49.6 (95% confidence interval [CI] 44.8-54.9) vs 16.5 (95% CI 13.0-20.9), with a geometric means ratio of 3.0 (95% CI 2.4-3.8). Among 102 participants who received the third dose at a median of 15 weeks from the second dose, the geometric means of sVNT increased to 73.3 (95% CI 69.0-77.8) and pseudovirus NT increased to 326 (95% CI 256-415). CONCLUSION: The extended 8-week interval regimen of BNT162b2 induced higher neutralizing antibodies than a standard 3-week interval regimen. The third dose induced high neutralizing antibodies against the Omicron variant. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023-05 2023-02-24 /pmc/articles/PMC10011807/ /pubmed/36841501 http://dx.doi.org/10.1016/j.ijid.2023.02.017 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Chantasrisawad, Napaporn
Techasaensiri, Chonnamet
Kosalaraksa, Pope
Phongsamart, Wanatpreeya
Tangsathapornpong, Auchara
Jaru-Ampornpan, Peera
Sophonphan, Jiratchaya
Suntarattiwong, Piyarat
Puthanakit, Thanyawee
The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
title The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
title_full The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
title_fullStr The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
title_full_unstemmed The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
title_short The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
title_sort immunogenicity of an extended dosing interval of bnt162b2 against sars-cov-2 omicron variant among healthy school-aged children, a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011807/
https://www.ncbi.nlm.nih.gov/pubmed/36841501
http://dx.doi.org/10.1016/j.ijid.2023.02.017
work_keys_str_mv AT chantasrisawadnapaporn theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT techasaensirichonnamet theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT kosalaraksapope theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT phongsamartwanatpreeya theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT tangsathapornpongauchara theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT jaruampornpanpeera theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT sophonphanjiratchaya theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT suntarattiwongpiyarat theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT puthanakitthanyawee theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT theimmunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT chantasrisawadnapaporn immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT techasaensirichonnamet immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT kosalaraksapope immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT phongsamartwanatpreeya immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT tangsathapornpongauchara immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT jaruampornpanpeera immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT sophonphanjiratchaya immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT suntarattiwongpiyarat immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT puthanakitthanyawee immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial
AT immunogenicityofanextendeddosingintervalofbnt162b2againstsarscov2omicronvariantamonghealthyschoolagedchildrenarandomizedcontrolledtrial